drugset / Trial / NCT00864149

A Relative Bioavailability Study of Carvedilol 12.5 mg Tablets Under Non-fasting Conditions

NCT00864149

Phase 1 Completed 36 enrolled Actavis Inc.
RandomizedCrossoverOpen-label

Summary

To compare the rate and extent of absorption of carvedilol from a test formulation of Carvedilol 12.5 mg Tablets versus the reference Coreg® 12.5 mg Tablets under fed conditions.

Timeline

Start
2005-10
Primary completion
2005-11
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Carvedilol Other / unclassified 12.5 mg

Indications

No indication recorded.